← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 150개
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab + Carboplatin + Pemetrexed)

Nonsquamous Non-small Cell Lung Cancer · Nonsquamous Non-small Cell Lung Cancer

#NonsquamousNon-smallCellLungCanc#Antibody#Phase2#항체#면역항체+2
효능 ORR 84%임상시험 1상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab Immunotherapy)

Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab plus Bevacizumab)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.3%임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 3

pembrolizumab (Keytruda, Pembrolizumab, Sintilimab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Olaparib; Bevacizumab (QLS5132; Olaparib; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
ADCBiologicstaleSutro Biopharma, Inc.Phase 1

STRO-004 (STRO-004)

Head and Neck Squamous Cell Carcinoma HNSCC; Non-Small Cell Lung Cancer NSCLC · Head and Neck Squamous Cell Carcinoma HN

#HeadandNeckSquamousCellCarcinoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Serplulimab combined with bevacizumab and first-line chemotherapy (Serplulimab combined with bevacizumab and first-line chemotherapy)

Non-small Cell Lung Cancer Stage II; Bevacizumab · Non-small Cell Lung Cancer Stage II

#Non-smallCellLungCancerStageII#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleXin-Hua XuPhase 2

Sindillimab (Sindillimab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
ADCBiologicstaleTubulis GmbHPhase 2

TUB-040 (TUB-040)

Ovarian Cancer; Non-small Cell Lung Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleCentre Hospitalier Universitair…Phase 2

nivolumab (Opdivo, UCPVax + Nivolumab)

Advanced Non-small Cell Lung Cancer · Advanced Non-small Cell Lung Cancer

#AdvancedNon-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleCatalYm GmbHPhase 2

Visugromab (Visugromab)

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleCatalYm GmbHPhase 2

recommended dose for expansion (Visugromab RDE, Visugromab RDE (recommended dose for expansion))

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#항체#면역항체+3
효능 ORR 100%임상시험 1상태 RECRUITING
AntibodystaleXencor, Inc.Phase 2

Vudalimab + Carboplatin + Pemetrexed (Vudalimab + Carboplatin + Pemetrexed)

Nonsquamous Non-small Cell Lung Cancer · Nonsquamous Non-small Cell Lung Cancer

#NonsquamousNon-smallCellLungCanc#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleZymeworks BC Inc.Phase 1

ZW251 (ZW251)

Hepatocellular Carcinoma; Squamous Cell Non-Small Cell Lung Cancer · Hepatocellular Carcinoma

#HepatocellularCarcinoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleJiangsu Cancer Institute & Hosp…Phase 2

QL1706 (apalolimab and toripalimab, apalolimab and toripalimab (QL1706))

NSCLC; NSCLC (Non-small Cell Lung Cancer) · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

7 / 8 페이지

← 이전다음 →